Abstract
The kidneys filter large amounts of glucose. To prevent the loss of this valuable fuel, the tubular system of the kidney, particularly the proximal tubule, has been programmed to reabsorb all filtered glucose. The machinery involves the sodium-glucose cotransporters SGLT2 and SGLT1 on the apical membrane and the facilitative glucose transporter GLUT2 on the basolateral membrane. The proximal tubule also generates new glucose, particularly in the post-absorptive phase but also to enhance bicarbonate formation and maintain acid-base balance. The glucose reabsorbed or formed by the proximal tubule is primarily taken up into peritubular capillaries and returned to the systemic circulation or provided as an energy source to further distal tubular segments that take up glucose by basolateral GLUT1. Recent studies provided insights on the coordination of renal glucose reabsorption, formation, and usage. Moreover, a better understanding of renal glucose transport in disease states is emerging. This includes the kidney in diabetes mellitus, when renal glucose retention becomes maladaptive and contributes to hyperglycemia. Furthermore, enhanced glucose reabsorption is coupled to sodium retention through the sodium-glucose cotransporter SGLT2, which induces secondary deleterious effects. As a consequence, SGLT2 inhibitors are new anti-hyperglycemic drugs that can protect the kidneys and heart from failing. Recent studies discovered unique roles for SGLT1 with implications in acute kidney injury and glucose sensing at the macula densa. This review discusses established and emerging concepts of renal glucose transport, and outlines the need for a better understanding of renal glucose handling in health and disease.
Similar content being viewed by others
References
Ackermann TF, Boini KM, Volkl H, Bhandaru M, Bareiss PM, Just L, Vallon V, Amann K, Kuhl D, Feng Y, Hammes HP, Lang F (2009) SGK1-sensitive renal tubular glucose reabsorption in diabetes. Am J Physiol Ren Physiol 296:F859–F866. https://doi.org/10.1152/ajprenal.90238.2008
Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A (2007) Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 18:1292–1298. https://doi.org/10.1681/ASN.2006070756
Ash SR, Cuppage FE (1970) Shift toward anaerobic glycolysis in the regenerating rat kidney. Am J Pathol 60:385–402
Balen D, Ljubojevic M, Breljak D, Brzica H, Zlender V, Koepsell H, Sabolic I (2008) Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Phys Cell Phys 295:C475–C489. https://doi.org/10.1152/ajpcell.00180.2008
Bankir L, Yang B (2012) New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism. Kidney Int 81:1179–1198. https://doi.org/10.1038/ki.2012.67
Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Phys 241:F322–F332
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384. https://doi.org/10.1016/S2213-8587(13)70208-0
Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Compr Physiol 2:1303–1353. https://doi.org/10.1002/cphy.c110041
Blantz RC, Peterson OW, Gushwa L, Tucker BJ (1982) Effect of modest hyperglycemia on tubuloglomerular feedback activity. Kidney Int Suppl 12:S206–S212
van Bommel EJ, Muskiet MH, van Baar MJB (2019) Dapagliflozin reduces measured GFR by reducing renal efferent arteriolar resistance in type 2 diabetes. Diabetes American Diabetes Association 79th scientific sessions:S-157 (abstract)
Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121:4210–4221. https://doi.org/10.1172/JCI45161
Burch HB, Narins RG, Chu C, Fagioli S, Choi S, McCarthy W, Lowry OH (1978) Distribution along the rat nephron of three enzymes of gluconeogenesis in acidosis and starvation. Am J Phys 235:F246–F253. https://doi.org/10.1152/ajprenal.1978.235.3.F246
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de ZD, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW (2019) Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.119.044359
Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A (2019) Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol 18:20. https://doi.org/10.1186/s12933-019-0828-y
Chen H, Busse LW (2017) Novel therapies for acute kidney injury. Kidney Int Rep 2:785–799. https://doi.org/10.1016/j.ekir.2017.06.020
Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1:57–92. https://doi.org/10.1007/s13300-010-0006-4
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatte M (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587–597. https://doi.org/10.1161/CIRCULATIONAHA.113.005081
Chin E, Zhou J, Bondy C (1993) Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest 91:1810-1815. doi:https://doi.org/10.1172/JCI116392 [doi]
Chin E, Zamah AM, Landau D, Gronbcek H, Flyvbjerg A, LeRoith D, Bondy CA (1997) Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology 138:1267–1275
Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi JI, Nakanishi T, Tamai I (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391–404. https://doi.org/10.1002/bdd.1909
Coady MJ, El TA, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY (2017) MAP17 is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85–93. https://doi.org/10.1681/ASN.2015111282
Conjard A, Martin M, Guitton J, Baverel G, Ferrier B (2001) Gluconeogenesis from glutamine and lactate in the isolated human renal proximal tubule: longitudinal heterogeneity and lack of response to adrenaline. Biochem J 360:371–377
Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20:1988–1993. https://doi.org/10.1111/dom.13301
Dominguez JH, Camp K, Maianu L, Garvey WT (1992) Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Phys 262:F807–F812
Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT (1994) Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Phys 266:F283–F290
Drewnowsk KD, Craig MR, Digiovanni SR, McCarty JM, Moorman AF, Lamers WH, Schoolwerth AC (2002) PEPCK mRNA localization in proximal tubule and gene regulation during metabolic acidosis. J Physiol Pharmacol 53:3–20
Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Moller M, Jorgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL (2019) Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med:8. https://doi.org/10.3390/jcm8060779
Eskandari S, Wright EM, Loo DD (2005) Kinetics of the reverse mode of the Na+/glucose cotransporter. J Membr Biol 204:23–32. https://doi.org/10.1007/s00232-005-0743-x
Faham S, Watanabe A, Besserer GM, Cascio D, Specht A, Hirayama BA, Wright EM, Abramson J (2008) The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science 321:810–814. https://doi.org/10.1126/science.1160406
FARBER SJ, BERGER EY, EARLE DP (1951) Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125–129. https://doi.org/10.1172/JCI102424
Farsijani NM, Liu Q, Kobayashi H, Davidoff O, Sha F, Fandrey J, Ikizler TA, O’Connor PM, Haase VH (2016) Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J Clin Invest 126:1425–1437. https://doi.org/10.1172/JCI74997
Fattah H, Shigeoka A, Huang W, Patel R, Kasimsetty S, Singh P, McKay DB, Vallon V (2018) Diverse gene expression patterns of renal transporters in AKI. J Am Soc Nephrol 29:1045 (Abstract)
Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26:27–38. https://doi.org/10.1016/j.cmet.2017.04.011
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499-508. doi:72227 https://doi.org/10.1172/JCI72227
Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114. https://doi.org/10.2337/dc16-0330
Fiorentino M, Grandaliano G, Gesualdo L, Castellano G (2018) Acute kidney injury to chronic kidney disease transition. Contrib Nephrol 193:45–54. https://doi.org/10.1159/000484962
Foote C, Perkovic V, Neal B (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 9:117–123. https://doi.org/10.1177/1479164112441190
Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF (2008) Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149:717–724. https://doi.org/10.1210/en.2007-1088
Freitas HS, Schaan BD, David-Silva A, Sabino-Silva R, Okamoto MM, Alves-Wagner AB, Mori RC, Machado UF (2009) SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol Cell Endocrinol 305:63–70. https://doi.org/10.1016/j.mce.2009.02.014
Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V (2014) SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63(supplement 1):A132
Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V (2018) The organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Ren Physiol 315:F386–F394. https://doi.org/10.1152/ajprenal.00503.2017
Fukuzawa T, Fukazawa M, Ueda O, Shimada H, Kito A, Kakefuda M, Kawase Y, Wada NA, Goto C, Fukushima N, Jishage K, Honda K, King GL, Kawabe Y (2013) SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose. PLoS One 8:e56681. https://doi.org/10.1371/journal.pone.0056681
Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89
Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103:373–381. https://doi.org/10.1016/j.diabres.2013.12.052
Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Ren Physiol 307:F317–F325. https://doi.org/10.1152/ajprenal.00145.2014
Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136-142. doi:DME2894 [pii];https://doi.org/10.1111/j.1464-5491.2009.02894.x [doi]
Gerich JE, Meyer C, Woerle HJ, Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382–391
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559. https://doi.org/10.1056/NEJMoa0802743
Ghezzi C, Wright EM (2012) Regulation of the human Na+ dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 303:C348-C354. doi:ajpcell.00115.2012 [pii];https://doi.org/10.1152/ajpcell.00115.2012 [doi]
Ghezzi C, Gorraitz E, Hirayama BA, Loo DD, Grempler R, Mayoux E, Wright EM (2014) Fingerprints of hSGLT5 sugar and cation selectivity. Am J Phys Cell Phys 306:C864–C870. https://doi.org/10.1152/ajpcell.00027.2014
Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, Wright EM (2014) SGLT2 inhibitors act from the extracellular surface of the cell membrane. Phys Rep 2:pii: e12058. https://doi.org/10.14814/phy2.12058
Gilbert RE, Thorpe KE (2019) Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21:1996–2000. https://doi.org/10.1111/dom.13754
Goestemeyer AK, Marks J, Srai SK, Debnam ES, Unwin RJ (2007) GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia 50:2209–2217. https://doi.org/10.1007/s00125-007-0778-x
Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–196. https://doi.org/10.2337/db11-1029
Grempler R, Augustin R, Froehner S, Hildebrandt T, Simon E, Mark M, Eickelmann P (2012) Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett 586:248–253. https://doi.org/10.1016/j.febslet.2011.12.027
Guder WG, Ross BD (1984) Enzyme distribution along the nephron. Kidney Int 26:101–111
Guyton AC (1991) Blood pressure control—special role of the kidneys and body fluids. Science 252:1813–1816
Hallow KM, Gebremichael Y, Helmlinger G, Vallon V (2017) Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Ren Physiol 312:F819–F835. https://doi.org/10.1152/ajprenal.00497.2016
Han HJ, Lee YJ, Park SH, Lee JH, Taub M (2005) High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Ren Physiol 288:F988–F996. https://doi.org/10.1152/ajprenal.00327.2004
Hansell P, Welch WJ, Blantz RC, Palm F (2013) Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. Clin Exp Pharmacol Physiol 40:123–137. https://doi.org/10.1111/1440-1681.12034
Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, Klein T, Mayoux E (2014) The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther 350:657–664. https://doi.org/10.1124/jpet.114.213454
Hediger MA, Coady MJ, Ikeda TS, Wright EM (1987) Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 330:379–381. https://doi.org/10.1038/330379a0
Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2018) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28:368–375. https://doi.org/10.1681/ASN.2016030278
Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613–621. https://doi.org/10.1111/dom.12073
Heyman SN, Rosen S, Brezis M (1997) The renal medulla: life at the edge of anoxia. Blood Purif 15:232–242. https://doi.org/10.1159/000170341
Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel A, Tam J (2018) Modulation of renal GLUT2 by the cannabinoid-1 receptor: implications for the treatment of diabetic nephropathy. J Am Soc Nephrol 29:434–448. https://doi.org/10.1681/ASN.2017040371
Holtkamp FA, D. dZ, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287. https://doi.org/10.1038/ki.2011.79
Huang W, Patel R, Onishi A, Crespo-Masip M, Soleimani M, Freeman B, Vallon V (2018) Tubular NHE3 is a determinant of the acute natriuretic and chronic blood pressure lowering effect of the SGLT2 inhibitor empagliflozin. FASEB J 32, supplement no 1:620.617
Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Phys Cell Phys 300:C14–C21. https://doi.org/10.1152/ajpcell.00388.2010
Inoue BH, dos SL, Pessoa TD, Antonio EL, Pacheco BP, Savignano FA, Carraro-Lacroix LR, Tucci PJ, Malnic G, Girardi AC (2012) Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Phys Regul Integr Comp Phys 302:R166–R174. https://doi.org/10.1152/ajpregu.00127.2011
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356–363. https://doi.org/10.2337/dc17-1096
Jensen PK, Kristensen KS, Rasch R, Persson AEG (1988) Decreased sensitivity of the tubuloglomerular feedback mechanism in experimental diabetic rats. In: Persson AEG, Boberg U (eds) The juxtaglomerular apparatus. Elsevier, Amsterdam, pp 333–338
Johnston PA, Rennke H, Levinsky NG (1984) Recovery of proximal tubular function from ischemic injury. Am J Phys 246:F159–F166
Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shulman GI, Kibbey RG (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890–898. https://doi.org/10.2337/db10-1328
Kamran M, Peterson RG, Dominguez JH (1997) Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8:943–948
Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest, 10.1172/JCI116972 93:397–404
Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, Lanaspa MA, Nakagawa T, Johnson RJ (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29:3–8. https://doi.org/10.1016/j.ejim.2015.11.026
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130
Kellett GL, Brot-Laroche E, Mace OJ, Leturque A (2008) Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr 28:35–54. https://doi.org/10.1146/annurev.nutr.28.061807.155518
Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38:316–322. https://doi.org/10.2337/dc14-0920
Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K (1981) Substrate oxidation by isolated single nephron segments of the rat. Kidney Int 20:29–35
Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L (2016) The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 29:391–400. https://doi.org/10.1007/s40620-016-0261-1
Komers R, Lindsley JN, Oyama TT, Allison KM, Anderson S (2000) Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol Ren Physiol 279:F573–F583
Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520–526. https://doi.org/10.1038/clpt.2008.251
Kowalski GM, Bruce CR (2014) The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab 307:E859–E871. https://doi.org/10.1152/ajpendo.00165.2014
Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, Chen L, Mandrup-Poulsen T, Orskov C, Gribble FM, Reimann F, Wierup N, Tyrberg B, Holst JJ (2019) No direct effect of SGLT2 activity on glucagon secretion. Diabetologia 62:1011–1023. https://doi.org/10.1007/s00125-019-4849-6
Lambers Heerspink HJ, de ZD, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862. https://doi.org/10.1111/dom.12127
Lan R, Geng H, Singha PK, Saikumar P, Bottinger EP, Weinberg JM, Venkatachalam MA (2016) Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol 27:3356–3367. https://doi.org/10.1681/ASN.2015020177
Lang F, Gorlach A, Vallon V (2009) Targeting SGK1 in diabetes. Expert Opin Ther Targets 13:1303–1311. https://doi.org/10.1517/14728220903260807
Layton AT, Vallon V (2018) SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Ren Physiol 314:F969–F984. https://doi.org/10.1152/ajprenal.00551.2017
Layton AT, Vallon V, Edwards A (2015) Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Ren Physiol 308:F1343–F1357. https://doi.org/10.1152/ajprenal.00007.2015
Layton AT, Vallon V, Edwards A (2016) Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Ren Physiol 310:F1269–F1283. https://doi.org/10.1152/ajprenal.00543.2015
Lee WS, Kanai Y, Wells RG, Hediger MA (1994) The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269:12032–12039
Li Z, Agrawal V, Ramratnam M, Sharma RK, D’Auria S, Sincoular A, Jakubiak M, Music ML, Kutschke WJ, Huang XN, Gifford L, Ahmad F (2019) Cardiac sodium-glucose co-transporter 1 (SGLT1) is a novel mediator of ischemia/reperfusion injury. Cardiovasc Res. https://doi.org/10.1093/cvr/cvz037
Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, Rogers S (2006) Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Ren Physiol 290:F205–F213. https://doi.org/10.1152/ajprenal.00237.2004
Liu R, Carretero OA, Ren Y, Garvin JL (2005) Increased intracellular pH at the macula densa activates nNOS during tubuloglomerular feedback. Kidney Int 67:1837–1843. https://doi.org/10.1111/j.1523-1755.2005.00282.x
Lynch MR, Tran MT, Parikh SM (2018) PGC1alpha in the kidney. Am J Physiol Ren Physiol 314:F1–F8. https://doi.org/10.1152/ajprenal.00263.2017
Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Ren Physiol 308:F77–F83. https://doi.org/10.1152/ajprenal.00555.2014
Lytvyn Y, Bjornstad P, Katz A, Singh SK, Godoy LC, Chung LT, Vinovskis CL, Pyle L, Roussel R, Perkins BA, Cherney D (2019) SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes Metab. https://doi.org/10.1016/j.diabet.2019.11.006
Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, Poucher SM (2010) The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 12:1004–1012. https://doi.org/10.1111/j.1463-1326.2010.01291.x
Madunic IV, Breljak D, Karaica D, Koepsell H, Sabolic I (2017) Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pflugers Arch 469:1545–1565. https://doi.org/10.1007/s00424-017-2056-1
Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697. https://doi.org/10.1007/s00125-009-1268-0
Malek M, Nematbakhsh M (2015) Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 4:20-27. doi:https://doi.org/10.12861/jrip.2015.06 [doi]
Marks J, Carvou NJ, Debnam ES, Srai SK, Unwin RJ (2003) Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 553:137–145. https://doi.org/10.1113/jphysiol.2003.046268
Martin MG, Turk E, Lostao MP, Kerner C, Wright EM (1996) Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12:216-220. doi:https://doi.org/10.1038/ng0296-216 [doi]
Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, Nagata D (2018) Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Ren Physiol 315:F653–F664. https://doi.org/10.1152/ajprenal.00143.2018
Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D (2020) Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep 8:e14360. doi:https://doi.org/10.14814/phy2.14360
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509–514. https://doi.org/10.1172/JCI70704
Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101–109
Molitoris BA, Kinne R (1987) Ischemia induces surface membrane dysfunction. Mechanism of altered Na+-dependent glucose transport. J Clin Invest 80:647–654. https://doi.org/10.1172/JCI113117
Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457–466. https://doi.org/10.1111/dom.12244
Mueckler M, Thorens B (2013) The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34:121–138. https://doi.org/10.1016/j.mam.2012.07.001
Neal B, Perkovic V, Mahaffey KW, de ZD, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and |Abetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
Neill O, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes oxygen tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol 309:F227–F234. https://doi.org/10.1152/ajprenal.00689.2014
Nespoux J, Vallon V (2018) SGLT2 inhibition and kidney protection. Clin Sci (Lond) 132:1329–1339. https://doi.org/10.1042/CS20171298
Nespoux J, Vallon V (2019) Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. https://doi.org/10.1097/MNH.0000000000000584
Nespoux J, Patel R, Zhang H, Huang W, Freeman B, Sanders PW, Kim YC, Vallon V (2020) Gene knockout of the Na-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Ren Physiol. https://doi.org/10.1152/ajprenal.00607.2019
Nespoux J, Patel R, Hudkins KL, Huang W, Freeman B, Kim Y, Koepsell H, Alpers CE, Vallon V (2019) Gene deletion of the Na-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Ren Physiol 316:F1201–F1210
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845–854. https://doi.org/10.1016/S2213-8587(19)30256-6
Norton L, Shannon CE, Fourcaudot M, Hu C, Wang N, Ren W, Song J, Abdul-Ghani M, DeFronzo RA, Ren J, Jia W (2017) Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 19:1322–1326. https://doi.org/10.1111/dom.13003
Novikov A, Fu Y, Huang W, Freeman B, Patel R, van GC, Koepsell H, Busslinger M, Onishi A, Nespoux J, Vallon V (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Ren Physiol 316:F173–F185. https://doi.org/10.1152/ajprenal.00462.2018
Onishi A, Fu Y, Darshi M, Crespo-Masip M, Huang W, Song P, Patel R, Kim YC, Nespoux J, Freeman B, Soleimani M, Thomson SC, Sharma K, Vallon V (2019) Effect of renal tubule-specific knockdown of the Na(+)/H(+) exchanger NHE3 in Akita diabetic mice. Am J Physiol Ren Physiol 317:F419–F434. https://doi.org/10.1152/ajprenal.00497.2018
Osorio H, Bautista R, Rios A, Franco M, Santamaria J, Escalante B (2009) Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 86:e46–e49. https://doi.org/10.1016/j.diabres.2009.09.006
Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC (2004) GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol 150:627–633
Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2014) Sodium-glucose Cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480–1483. https://doi.org/10.2337/dc13-2338
Perkovic V, Jardine M, Vijapurkar U, Meininger G (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin 31:2219–2231. https://doi.org/10.1185/03007995.2015.1092128
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de ZD, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028–2039. https://doi.org/10.1681/ASN.2013060588
Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, Heerspink HJL (2017) Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12:751–759. https://doi.org/10.2215/CJN.10180916
Pfaff IL, Vallon V (2002) Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril. Kidney Blood Press Res 25:329–340
Pfaff IL, Wagner HJ, Vallon V (1999) Immunolocalization of protein kinase C isoenzymes alpha, beta1 and betaII in rat kidney. J Am Soc Nephrol 10:1861–1873
Phillips AO, Steadman R, Morrisey K, Williams JD (1997) Polarity of stimulation and secretion of transforming growth factor-beta 1 by cultured proximal tubular cells. Am J Pathol 150:1101–1111
Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117–E130. https://doi.org/10.1152/ajpendo.00439.2012
Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM (2014) Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther 350:232–242. https://doi.org/10.1124/jpet.114.214304
Pruijm M, Milani B, Pivin E, Podhajska A, Vogt B, Stuber M, Burnier M (2018) Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int 93:932–940. https://doi.org/10.1016/j.kint.2017.10.020
Qiu H, Novikov A, Vallon V (2017) Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 33:5. https://doi.org/10.1002/dmrr.2886
Quamme GA, Freeman HJ (1987) Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney. Am J Phys 253:F151–F157
Quinn PG, Yeagley D (2005) Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 5:423–437
Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427–3434
Rieg T, Vallon V (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079–2086. https://doi.org/10.1007/s00125-018-4654-7
Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol 306:F188–F193. https://doi.org/10.1152/ajprenal.00518.2013
Rosen S, Epstein FH, Brezis M (1992) Determinants of intrarenal oxygenation: factors in acute renal failure. Ren Fail 14:321–325
Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174–C1188. https://doi.org/10.1152/ajpcell.00450.2011
Sala-Rabanal M, Hirayama BA, Ghezzi C, Liu J, Huang SC, Kepe V, Koepsell H, Yu A, Powell DR, Thorens B, Wright EM, Barrio JR (2016) Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol 594:4425–4438. https://doi.org/10.1113/JP271904
Sano M, Takei M, Shiraishi Y, Suzuki Y (2016) Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8:844–847. https://doi.org/10.14740/jocmr2760w
Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133–141. https://doi.org/10.2215/CJN.04010609
Santer R, Schneppenheim R, Suter D, Schaub J, Steinmann B (1998) Fanconi-Bickel syndrome—the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr 157:783–797
Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, Leonard JV, Moses S, Norgren S, Skovby F, Schneppenheim R, Steinmann B, Schaub J (2002) The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet 110:21–29. https://doi.org/10.1007/s00439-001-0638-6
Saponaro C, Muhlemann M, Acosta-Montalvo A, Piron A, Gmyr V, Delalleau N, Moerman E, Thevenet J, Pasquetti G, Coddeville A, Cnop M, Kerr-Conte J, Staels B, Pattou F, Bonner C (2020) Inter-individual heterogeneity of SGLT2 expression and function in human pancreatic islets. Diabetes. https://doi.org/10.2337/db19-0888
Sasaki M, Sasako T, Kubota N, Sakurai Y, Takamoto I, Kubota T, Inagi R, Seki G, Goto M, Ueki K, Nangaku M, Jomori T, Kadowaki T (2017) Dual regulation of gluconeogenesis by insulin and glucose in the proximal tubules of the kidney. Diabetes 66:2339–2350. https://doi.org/10.2337/db16-1602
Satirapoj B, Korkiatpitak P, Supasyndh O (2019) Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial. Clin Kidney J 12:326–332. https://doi.org/10.1093/ckj/sfy122
Schmidt C, Hocherl K, Schweda F, Kurtz A, Bucher M (2007) Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 18:1072–1083. https://doi.org/10.1681/ASN.2006050454
Seidner G, Alvarez MG, Yeh JI, O’Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC (1998) GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188–191. https://doi.org/10.1038/ng0298-188
Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669–672. https://doi.org/10.1111/j.1463-1326.2011.01406.x
Shanley PF, Brezis M, Spokes K, Silva P, Epstein FH, Rosen S (1986) Transport-dependent cell injury in the S3 segment of the proximal tubule. Kidney Int 29:1033–1037
Shepard BD, Pluznick JL (2017) Saving the sweetness: renal glucose handling in health and disease. Am J Physiol Ren Physiol 313:F55–F61. https://doi.org/10.1152/ajprenal.00046.2017
Sims H, Smith KH, Bramlage P, Minguet J (2018) Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus. Diabet Med 35:1037–1048. https://doi.org/10.1111/dme.13645
Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E (2017) Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19:1289–1294. https://doi.org/10.1111/dom.12970
Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 20:1109–1125. https://doi.org/10.1517/14728222.2016.1168808
Song P, Huang W, Onishi A, Patel R, Kim Y, van Ginkel C, Fu Y, Freeman B, Koepsell H, Thomson SC, Liu R, Vallon V (2019) Knockout of Na-glucose-cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase-1 in macula densa and glomerular hyperfiltration. Am J Physiol Ren Physiol 317:F207–F217
Sotak M, Marks J, Unwin RJ (2017) Putative tissue location and function of the SLC5 family member SGLT3. Exp Physiol 102:5–13. https://doi.org/10.1113/EP086042
Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T (2019) SGLT1 in pancreatic alpha cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab 19:1–12. https://doi.org/10.1016/j.molmet.2018.10.009
Sugawara-Yokoo M, Suzuki T, Matsuzaki T, Naruse T, Takata K (1999) Presence of fructose transporter GLUT5 in the S3 proximal tubules in the rat kidney. Kidney Int 56:1022-1028. doi:S0085-2538(15)46380-X [pii];https://doi.org/10.1046/j.1523-1755.1999.00635.x [doi]
Swe MT, Pongchaidecha A, Chatsudthipong V, Chattipakorn N, Lungkaphin A (2019) Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions. J Cell Physiol 234:8134-8151. doi:https://doi.org/10.1002/jcp.27598 [doi]
Szablewski L (2017) Distribution of glucose transporters in renal diseases. J Biomed Sci 24:64. https://doi.org/10.1186/s12929-017-0371-7
Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M, Takemura Y, Maruyama H, Sugiyama T, Wakamatsu A, Isogai T, Isaji M (2005) SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 76:1039–1050. https://doi.org/10.1016/j.lfs.2004.10.016
Thomson SC, Vallon V (2019) Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol 124 Suppl 1:S28-S35. https://doi.org/10.1016/j.amjcard.2019.10.027
Thomson SC, Deng A, Komine N, Hammes JS, Blantz RC, Gabbai FB (2004) Early diabetes as a model for testing the regulation of juxtaglomerular NOS I. Am J Physiol Ren Physiol 287:F732–F738. https://doi.org/10.1152/ajprenal.00340.2003
Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Phys Regul Integr Comp Phys 302:R75–R83. https://doi.org/10.1152/ajpregu.00357.2011
Thorens B, Lodish HF, Brown D (1990) Differential localization of two glucose transporter isoforms in rat kidney. Am J Phys 259:C286–C294
Tiwari S, Riazi S, Ecelbarger CA (2007) Insulin’s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Ren Physiol 293:F974–F984. https://doi.org/10.1152/ajprenal.00149.2007
Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM (1993) Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Phys 265:F886–F895
Turner RJ, Moran A (1982) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Phys 242:F406–F414
Uchida S, Endou H (1988) Substrate specificity to maintain cellular ATP along the mouse nephron. Am J Phys 255:F977–F983
Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, Tokuyama H, Wakino S, Itoh H (2018) High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep 8:6791. https://doi.org/10.1038/s41598-018-25054-y
Vaduganathan M, Januzzi JL, Jr. (2019) Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors. Am J Cardiol 124 Suppl 1:S20-S27. https://doi.org/10.1016/j.amjcard.2019.10.026
Vallon V (2011) Molecular determinants of renal glucose transport. Am J Phys Cell Phys 300:C6–C8. https://doi.org/10.1152/ajpcell.00444.2010
Vallon V (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Phys Regul Integr Comp Phys 300:R1009–R1022. https://doi.org/10.1152/ajpregu.00809.2010
Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255–270
Vallon V (2016) Tubular transport in acute kidney injury: relevance for diagnosis, prognosis and intervention. Nephron 134:160–166. https://doi.org/10.1159/000446448
Vallon V, Osswald H (1994) Dipyridamole prevents diabetes-induced alterations of kidney function in rats. Naunyn Schmiedeberg's Arch Pharmacol 349:217–222
Vallon V, Thomson S (1995) Inhibition of local nitric oxide synthase increases homeostatic efficiency of tubuloglomerular feedback. Am J Phys 269:F892–F899
Vallon V, Thomson SC (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74:351–375. https://doi.org/10.1146/annurev-physiol-020911-153333
Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215–225. https://doi.org/10.1007/s00125-016-4157-3
Vallon V, Blantz RC, Thomson S (1995) Homeostatic efficiency of tubuloglomerular feedback is reduced in established diabetes mellitus in rats. Am J Phys 269:F876–F883
Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576
Vallon V, Grahammer F, Richter K, Bleich M, Lang F, Barhanin J, Volkl H, Warth R (2001) Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol 12:2003–2011
Vallon V, Traynor T, Barajas L, Huang YG, Briggs JP, Schnermann J (2001) Feedback control of glomerular vascular tone in neuronal nitric oxide synthase knockout mice. J Am Soc Nephrol 12:1599–1606
Vallon V, Blantz RC, Thomson S (2003) Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 14:530–537
Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, Gerlach U, Rong Q, Pfeifer K, Lang F (2005) KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A 102:17864–17869. https://doi.org/10.1073/pnas.0505860102
Vallon V, Muhlbauer B, Osswald H (2006) Adenosine and kidney function. Physiol Rev 86:901–940
Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–112
Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Ren Physiol 304:F156–F167. https://doi.org/10.1152/ajprenal.00409.2012
Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Ren Physiol 306:F194–F204. https://doi.org/10.1152/ajprenal.00520.2013
Vallon V, Broer S, Nigam SK (2020) Renal handling of organic solutes. In: Yu AS, Chertow G, Luyckx V, Marsden PA, Skorecki K, Taal MW (eds) Brenner & Rector’s the kidney, 11th edn. Elsevier, Philadelphia, pp 218–246
Vrhovac I, Balen ED, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, Jadrijevic S, Aleksic I, Walles T, Sauvant C, Sabolic I, Koepsell H (2015) Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881–1898. https://doi.org/10.1007/s00424-014-1619-7
Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D’Agati VD, Koepsell H, Kopp JB, Rosenberg A, Levi M (2017) SGLT2 expression is increased in human diabetic nephropathy: SGLT2 inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice. J Biol Chem 292:5335–5348. https://doi.org/10.1074/jbc.M117.779520
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von EM, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334. https://doi.org/10.1056/NEJMoa1515920
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von EM, Zinman B (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268
Weinberg JM, Molitoris BA (2009) Illuminating mitochondrial function and dysfunction using multiphoton technology. J Am Soc Nephrol 20:1164–1166. https://doi.org/10.1681/ASN.2009040419
Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Phys 263:F459–F465
Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HH (1992) Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A 89:11993–11997
Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89:3–9. https://doi.org/10.1079/BJN2002763
Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Ren Physiol 280:F10–F18
Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Asp Med 34:183–196. https://doi.org/10.1016/j.mam.2012.11.002
Wright EM, Turk E (2004) The sodium/glucose cotransport family SLC5. Pflugers Arch 447:510–518. https://doi.org/10.1007/s00424-003-1063-6
Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733-794. doi:91/2/733 [pii];https://doi.org/10.1152/physrev.00055.2009 [doi]
Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463–473. https://doi.org/10.1111/dom.12090
You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA (1995) Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270:29365–29371
Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YM (2014) Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem 289:346–357. https://doi.org/10.1074/jbc.M113.526814
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X
Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A (2018) A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94:524–535. https://doi.org/10.1016/j.kint.2018.05.002
Zhang J, Wei J, Jiang S, Xu L, Wang L, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R (2019) Macula densa SGLT1-NOS1-TGF pathway—a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol 30:578–593
Zierler K (1999) Whole body glucose metabolism. Am J Phys 276:E409–E426
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
Funding
The author was supported by NIH grants R01DK112042, R01DK106102, R01HL142814, RF1AG061296, the UAB/UCSD O’Brien Center of Acute Kidney Injury NIH-P30DK079337, and the Department of Veterans Affairs.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Over the past 36 months, VV has served as a consultant and received honoraria from Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceutical, Merck, and Retrophin, and received grant support for investigator-initiated research from Astra-Zeneca, Bayer, Boehringer Ingelheim, Fresenius, Janssen, and Novo-Nordisk.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the special issue on Glucose Transporters in Health and Disease in Pflügers Archiv—European Journal of Physiology
Rights and permissions
About this article
Cite this article
Vallon, V. Glucose transporters in the kidney in health and disease. Pflugers Arch - Eur J Physiol 472, 1345–1370 (2020). https://doi.org/10.1007/s00424-020-02361-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00424-020-02361-w